These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29807436)

  • 1. Therapeutic drug monitoring of tumour necrosis factor inhibitors in the management of chronic inflammatory diseases.
    Sanchez-Hernandez JG; Rebollo N; Munoz F; Martin-Suarez A; Calvo MV
    Ann Clin Biochem; 2019 Jan; 56(1):28-41. PubMed ID: 29807436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases.
    Felice C; Marzo M; Pugliese D; Papa A; Rapaccini GL; Guidi L; Armuzzi A
    Expert Opin Biol Ther; 2015; 15(8):1107-17. PubMed ID: 25947043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.
    Vande Casteele N; Gils A
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S39-50. PubMed ID: 25707962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.
    Oude Munnink TH; Henstra MJ; Segerink LI; Movig KL; Brummelhuis-Visser P
    Clin Pharmacol Ther; 2016 Apr; 99(4):419-31. PubMed ID: 26265133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics in IBD: ready for prime time?
    Roblin X; Rinaudo M; Sparrow MP; Moreau A; Phelip JM; Genin C; Lamarque D; Paul S
    Curr Drug Targets; 2014; 15(11):1049-55. PubMed ID: 25173707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of biologics and the role of therapeutic monitoring.
    Lin K; Mahadevan U
    Gastroenterol Clin North Am; 2014 Sep; 43(3):565-79. PubMed ID: 25110259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic concentration testing in inflammatory bowel disease.
    Vaughn BP; Sandborn WJ; Cheifetz AS
    Inflamm Bowel Dis; 2015 Jun; 21(6):1435-42. PubMed ID: 25590953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring in inflammatory bowel disease.
    Jossen J; Dubinsky M
    Curr Opin Pediatr; 2016 Oct; 28(5):620-5. PubMed ID: 27583410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
    Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
    Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
    Khanna R; Sattin BD; Afif W; Benchimol EI; Bernard EJ; Bitton A; Bressler B; Fedorak RN; Ghosh S; Greenberg GR; Marshall JK; Panaccione R; Seidman EG; Silverberg MS; Steinhart AH; Sy R; Van Assche G; Walters TD; Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2013 Sep; 38(5):447-59. PubMed ID: 23848220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.
    Brun MK; Gehin JE; Bjørlykke KH; Warren DJ; Klaasen RA; Sexton J; Sandanger Ø; Kvien TK; Mørk C; Jahnsen J; Bolstad N; Jørgensen KK; Haavardsholm EA; Goll GL; Syversen SW
    Lancet Rheumatol; 2024 Apr; 6(4):e226-e236. PubMed ID: 38402891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug monitoring of biologics in inflammatory bowel disease.
    Eser A; Primas C; Reinisch W
    Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
    Franca R; Curci D; Lucafò M; Decorti G; Stocco G
    Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
    [No Abstract]   [Full Text] [Related]  

  • 17. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F; Chiappelli M; Ianni M; Porcellini E
    Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
    Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
    Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases.
    Vande Casteele N; Herfarth H; Katz J; Falck-Ytter Y; Singh S
    Gastroenterology; 2017 Sep; 153(3):835-857.e6. PubMed ID: 28774547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.